Ardelyx focuses on developing first-in-class medicines for patients with unmet medical needs, particularly in the areas of chronic kidney disease and irritable bowel syndrome.

Ardelyx

IPhone / Mobile Compatible

Viewport Meta

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

Google Analytics

DNSSEC

Content Delivery Network

Vice President Legal and Chief Compliance Officer

Daina Selvig

Chief Legal and Administrative Officer

Elizabeth Grammer

President & CEO

Mike Raab

Chief People Officer

Sarah O'Brien

Vice President, Biology

Hicham Alaoui

VP, Government Affairs & Policy

Tricia Brooks

Senior Director, Patient Advocacy

Alan Ryan

Area Business Director

Alicia Thorpe

Angela Bolick

Area Business Director Ardelyx, Inc

Ann Pinnata

David Mott

Jean Fréchet

David Rosenbaum

SVP, Drug Development & CDO

Peter G. Schultz

Co-Founder and Director

Andrew Spencer

Senior Director, R&D Alliance Management

Robert Blanks

Chief Regulatory and Quality Officer

Susan Rodriguez

Chief Commercial Officer

Dominique Charmot

Co-founder and Chief Scientific Officer

Mike Kelliher

Executive Vice President of Corporate Development

Western US Public Companies With More Than $100M in Revenue

West Coast Public Companies With More Than $1M in Revenue

West Coast Companies With Fewer Than 1000 Employees (Top 10K)

Foresite Capital Portfolio Companies

Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Company's molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. The Company's non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure. The Company's lead product, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a minimally-absorbed, orally administered NaP2b phosphate transport inhibitor for the inhibition of phosphate absorption in patients with chronic kidney disease, and RDX009, a minimally-absorbed, orally administered TGR5 agonist for the treatment of type 2 diabetes through direct induction of intestinal incretins such as GLP-1 and PYY. Both RDX002 and RDX009 are in preclinical development. To date, Ardelyx has raised $56M in venture and angel funding since it was founded in 2007. Ardelyx is located in Fremont, California.

HealthCare Royalty Partners

Post-IPO Debt - Ardelyx

SLR Capital Partners

Post-IPO Equity - Ardelyx

New Enterprise Associates

Amgen Ventures

Series B - Ardelyx

Debt Financing - Ardelyx

CMEA Capital

Series A - Ardelyx

Fremont

California

United States

North America

Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop

Ardelyx announces presentation of Xphozah data at Kidney Week

ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx

An investigational compound for the treatment of hyperkalemia, targeting potassium secretion in the gut.

A research program focused on developing treatments for metabolic acidosis by inhibiting intestinal bicarbonate exchange.

Approved in Japan for hyperphosphatemia, it targets cardiorenal diseases and conditions.

Available in Canada for IBS-C, it represents Ardelyx's efforts in addressing irritable bowel syndrome with constipation.

Russian Federation

Europe

Malaysia

Asia

India

Pakistan

HTML5

Google Maps API

jQuery

Office 365

Modernizr

F5 NGINX

Vimeo

DigiCert

Wordpress

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

news impact assignment basic	general
public peers	general	Oct 16, 2024 5:38 AM	64077f43
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 5:38 AM	5d8cf499
crunchbase trigger	general	Nov 27, 2024 12:50 PM	4cad6fb4
crunchbase profile	general	Nov 28, 2024 9:39 AM	206f2bd2
li profile	general
translate crunchbase fundingrounds	general	Nov 28, 2024 11:12 AM	0b080952
peers	general	Oct 16, 2024 5:38 AM	5be93948
news basic	general	Oct 16, 2024 5:38 AM	92e8a33a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ARDELYX

Ardelyx

Last Close

5.12

22/11 21:00

Market Cap

1.30B

Beta: -

Volume Today

3.79M

Avg: -